Literature DB >> 24037872

Imaging EGFR and HER2 by PET and SPECT: a review.

Emily B Corcoran1, Robert N Hanson.   

Abstract

In an effort to discover a noninvasive method for predicting which cancer patients will benefit from therapy targeting the EGFR and HER2 proteins, a large body of the research has been conducted toward the development of PET and SPECT imaging agents, which selectively target these receptors. We provide a general overview of the advances made toward imaging EGFR and HER2, detailing the investigation of PET and SPECT imaging agents ranging in size from small molecules to monoclonal antibodies.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  EGFR; HER2; PET; SPECT

Mesh：

Substances：

Year:  2013        PMID： 24037872     DOI： 10.1002/med.21299

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


  26 in total

1.  Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.

Authors:  Longguang Tang; Chenyu Peng; Bowen Tang; Zijing Li; Xiangyu Wang; Jindian Li; Fei Gao; Lumei Huang; Duo Xu; Pu Zhang; Rongqiang Zhuang; Xinhui Su; Xiaoyuan Chen; Xianzhong Zhang
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

2.  Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Authors:  Aaron N Hata; Harald Paganetti; Clemens Grassberger; David McClatchy; Changran Geng; Sophia C Kamran; Florian Fintelmann; Yosef E Maruvka; Zofia Piotrowska; Henning Willers; Lecia V Sequist
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

3.  PET imaging of EGFR expression using an 18F-labeled RNA aptamer.

Authors:  Siyuan Cheng; Orit Jacobson; Guizhi Zhu; Zhen Chen; Steve H Liang; Rui Tian; Zhen Yang; Gang Niu; Xiaohua Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-01       Impact factor: 9.236

4.  PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.

Authors:  Shibo Qi; Susan Hoppmann; Yingding Xu; Zhen Cheng
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

5.  A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.

Authors:  Max A Kruziki; Sumit Bhatnagar; Daniel R Woldring; Vandon T Duong; Benjamin J Hackel
Journal:  Chem Biol       Date:  2015-07-09

6.  Preclinical characterization and validation of a dual-labeled trastuzumab-based imaging agent for diagnosing breast cancer.

Authors:  Xuejuan Wang; Melissa B Aldrich; Milton V Marshall; Eva M Sevick-Muraca
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

7.  Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Authors:  Irina Velikyan; Anders Wennborg; Joachim Feldwisch; Henrik Lindman; Jörgen Carlsson; Jens Sörensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24

Review 8.  Theranostic applications of antibodies in oncology.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Sandra Heskamp; Carla M L van Herpen; Wim J G Oyen; Winette T A van der Graaf; Otto C Boerman
Journal:  Mol Oncol       Date:  2014-03-21       Impact factor: 6.603

Review 9.  Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.

Authors:  Lemonitsa H Mammatas; Henk M W Verheul; N Harry Hendrikse; Maqsood Yaqub; Adriaan A Lammertsma; C Willemien Menke-van der Houven van Oordt
Journal:  Cell Oncol (Dordr)       Date:  2014-09-24       Impact factor: 6.730

10.  Multimodal Bone Metastasis-associated Epidermal Growth Factor Receptor Imaging in an Orthotopic Rat Model.

Authors:  Tobias Bäuerle; Suresh Gupta; Shaokuan Zheng; Lisa Seyler; Anita Leporati; Miklos Marosfoi; Simone Maschauer; Olaf Prante; Peter Caravan; Alexei Bogdanov
Journal:  Radiol Imaging Cancer       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.